Stoneridge Investment Partners LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 14.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,737 shares of the company’s stock after acquiring an additional 5,006 shares during the period. Johnson & Johnson accounts for 3.8% of Stoneridge Investment Partners LLC’s holdings, making the stock its 5th biggest position. Stoneridge Investment Partners LLC’s holdings in Johnson & Johnson were worth $6,843,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Glassy Mountain Advisors Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $35,000. Retirement Financial Solutions LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $40,000. TD Capital Management LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth $48,000. VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $52,000. Finally, Iron Horse Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after buying an additional 159 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Stock Down 1.3 %
Shares of NYSE JNJ opened at $162.87 on Thursday. The company’s 50-day simple moving average is $158.10 and its 200-day simple moving average is $167.02. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The firm has a market cap of $424.16 billion, a price-to-earnings ratio of 34.07, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.92%. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on JNJ shares. StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Atlantic Securities cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Raymond James cut their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. Finally, Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.00.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Starbucks Stock Becomes a Value Play
- Kraft Heinz Recovery Gains Momentum
- Here’s Why AMD’s Weak Guidance Is A Blessing In Disguise
- BP Shares Sold Off After Earnings: Here Is What Upset Markets
- Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
